

# Jan Heyckendorf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9193979/publications.pdf>

Version: 2024-02-01

53  
papers

1,846  
citations

361413

20  
h-index

289244

40  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence of bedaquiline resistance in a high tuberculosis burden country. <i>European Respiratory Journal</i> , 2022, 59, 2100621.	6.7	48
2	Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. <i>European Respiratory Journal</i> , 2022, 60, 2102263.	6.7	17
3	Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0022721.	13.6	26
4	Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing. <i>Genome Medicine</i> , 2022, 14, 52.	8.2	14
5	Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis. <i>ACS Infectious Diseases</i> , 2022, 8, 1303-1315.	3.8	9
6	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
7	Rapid genomic first- and second-line drug resistance prediction from clinical <i>Mycobacterium tuberculosis</i> specimens using Deeplex-MycTB. <i>European Respiratory Journal</i> , 2021, 57, 2001796.	6.7	47
8	Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. <i>Respiration</i> , 2021, 100, 843-852.	2.6	8
9	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021, 58, 2003492.	6.7	27
10	Tuberculosis endotypes to guide stratified host-directed therapy. <i>Med</i> , 2021, 2, 217-232.	4.4	24
11	Pulmonary vasculitis due to infection with <i>Mycobacterium goodii</i> : A case report. <i>International Journal of Infectious Diseases</i> , 2021, 104, 178-180.	3.3	0
12	Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing. <i>Clinical Infectious Diseases</i> , 2021, 73, 1194-1202.	5.8	21
13	Swarm Learning for decentralized and confidential clinical machine learning. <i>Nature</i> , 2021, 594, 265-270.	27.8	375
14	Perspectives for systems biology in the management of tuberculosis. <i>European Respiratory Review</i> , 2021, 30, 200377.	7.1	13
15	Pathogen-free diagnosis of tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1066.	9.1	0
16	Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. <i>European Respiratory Journal</i> , 2021, 57, 2002544.	6.7	15
17	Intensified adjunctive corticosteroid therapy for CNS tuberculomas. <i>Infection</i> , 2020, 48, 289-293.	4.7	6
18	Changes in taste and smell as an early marker for COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 99, 8-9.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Perspective for Precision Medicine for Tuberculosis. <i>Frontiers in Immunology</i> , 2020, 11, 566608.	4.8	35
20	Culture-free proof of <i>Mycobacterium tuberculosis</i> - a new assay for viable bacteria. <i>EBioMedicine</i> , 2020, 62, 103117.	6.1	4
21	Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1564-1568.	5.6	59
22	Burden and Characteristics of the Comorbidity Tuberculosisâ€”Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.9	12
23	Failing treatment of multidrug-resistant tuberculosis: a matter of definition. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 522-524.	1.2	10
24	New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 514-515.	5.6	10
25	Clofazimine for the treatment of multidrug-resistant tuberculosis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 128-130.	6.0	19
26	Relapse-free cure from multidrug-resistant tuberculosis in Germany. <i>European Respiratory Journal</i> , 2018, 51, 1702122.	6.7	17
27	Drugâ€”resistant tuberculosis: An update on disease burden, diagnosis and treatment. <i>Respirology</i> , 2018, 23, 656-673.	2.3	159
28	Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. <i>European Respiratory Journal</i> , 2018, 51, 1702189.	6.7	12
29	What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	83
30	Evaluation of Galactomannan Testing, the <i>Aspergillus</i> -Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. <i>Frontiers in Microbiology</i> , 2018, 9, 2223.	3.5	23
31	Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. <i>Respiration</i> , 2018, 96, 283-301.	2.6	42
32	An Unexpected Endobronchial Mass Appearing During Bronchoscopy. <i>Chest</i> , 2018, 154, e13-e21.	0.8	1
33	<i>Mycobacterium</i> Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following <i>Mycobacterium bovis</i> Bacille Calmetteâ€”GuÃ©rin Vaccination. <i>Frontiers in Immunology</i> , 2018, 9, 1708.	4.8	5
34	Characterization of patients with chronic pulmonary aspergillosis according to the new <sc>ESCMID</sc>/<sc>ERS</sc>/<sc>ECMM</sc> and <sc>IDSA</sc> guidelines. <i>Mycoses</i> , 2017, 60, 136-142.	4.0	40
35	Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1700742.	6.7	32
36	High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. <i>European Respiratory Journal</i> , 2017, 50, 1701340.	6.7	5

#	ARTICLE	IF	CITATIONS
37	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
38	Chronic Cough and Severe Weight Loss in a 55-Year-Old Previously Healthy Man. <i>Clinical Infectious Diseases</i> , 2017, 65, 349-351.	5.8	3
39	Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. <i>Infection</i> , 2017, 45, 269-276.	4.7	32
40	Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs. <i>Tuberculosis</i> , 2017, 102, 31-33.	1.9	3
41	Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the <i>katG</i> 315T mutation. <i>European Respiratory Journal</i> , 2017, 50, 1701752.	6.7	5
42	The best of respiratory infections from the 2015 European Respiratory Society International Congress. <i>ERJ Open Research</i> , 2016, 2, 00049-2016.	2.6	0
43	Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis. <i>Respiration</i> , 2016, 92, 199-214.	2.6	18
44	Thermostability of IFN- $\beta$ and IP-10 release assays for latent infection with <i>Mycobacterium tuberculosis</i> : A TBnet study. <i>Tuberculosis</i> , 2016, 98, 7-12.	1.9	7
45	Personalized medicine for patients with MDR-TB: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 852-855.	3.0	31
46	Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension. <i>Scientific Reports</i> , 2015, 4, 4808.	3.3	17
47	Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection. <i>Emerging Infectious Diseases</i> , 2015, 21, 1685-1687.	4.3	4
48	T-Cell Therapy: Options for Infectious Diseases: Table 1. <i>Clinical Infectious Diseases</i> , 2015, 61, S217-S224.	5.8	42
49	Novel drugs against tuberculosis: a clinician's perspective. <i>European Respiratory Journal</i> , 2015, 45, 1119-1131.	6.7	67
50	Getting Personal Perspectives on Individualized Treatment Duration in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 374-383.	5.6	39
51	Beyond the IFN- $\gamma$ horizon: biomarkers for immunodiagnosis of infection with <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2014, 43, 1472-1486.	6.7	135
52	Development of a One-Step Probe Based Molecular Assay for Rapid Immunodiagnosis of Infection with <i>M. tuberculosis</i> Using Dried Blood Spots. <i>PLoS ONE</i> , 2014, 9, e105628.	2.5	18
53	Time to Culture Positivity and Sputum Smear Microscopy during Tuberculosis Therapy. <i>PLoS ONE</i> , 2014, 9, e106075.	2.5	38